Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
2 clinical trials · 2 recruiting · INDUSTRY
Trials by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
RECRUITINGPhase 1NCT05869955
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases...
The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases...
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyEnrolling: 27020 locations
Systemic Lupus ErythematosusIdiopathic Inflammatory MyopathySystemic Sclerosis+1
RECRUITINGPhase 1NCT06220201
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing...
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS),...
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyEnrolling: 12020 locations
Multiple SclerosisMyasthenia Gravis